; and (2) in conjunction with the Administrator of the Drug Enforcement Administration, shall brief the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives on— (A) interim results from the studies described in paragraph (1); and (B) any barriers that may prevent adequate and timely enrollment of patients in any new clinical study described in paragraph (1). (b) Study on medication treatments for opioid use disorders The Secretary of Health and Human Services, acting through the Assistant Secretary for Mental Health and Substance Use, shall— (1) study— (A) the early impact on access to medication treatment for opioid use disorder and opioid-related overdose deaths through buprenorphine prescribing pursuant to section 303(g) of the Controlled Substances Act ( 21 U.S.C. 823(g) ), as amended by section 1262 of title I of division FF of the Mental Health and Well-Being Act of 2022; (B) an updated analysis of the effect of methadone on opioid-related overdose death rates, disaggregated by State; (C) the number of patients with opioid use disorder who are prescribed no medication for such disorder, and the number of patients with opioid use disorder who are prescribed naltrexone, buprenorphine, or methadone, respectively, at each opioid treatment program; (D) the prevalence of patients with opioid use disorder, disaggregated by county and the number of patients with opioid use disorder in each county; (E) the number of addiction psychiatrists and addiction medicine physicians within a county who are not affiliated with an opioid treatment program and, with respect to such psychiatrists and physicians— (i) whether such providers accept new patients; (ii) which types of health insurance are accepted by such providers; and (iii) wait times for new appointments